Deep Tech Startups

Butterfly Ventures is a seed-stage venture capital firm founded in 2012 that invests in deep tech, hardware, and hardware-interfacing software startups with social or environmental impact. It focuses primarily on Finland and Sweden, along with other Nordic and Baltic countries, typically making its first investment before companies generate revenue.

1 investor

MMT develops nondestructive material testing and toughness verification technologies, including HSD (hardness, strength, ductility) and BTM (blade toughness meter) testers, to measure the durability of pipelines and other infrastructure without service interruption. It serves pipeline operators and NDE service providers, delivering data analysis and fit-for-purpose reports to meet regulatory requirements such as PHMSA's Mega Rule.

1 investor

Byorna develops a bioproduction platform that uses eukaryotic cell biofactories to manufacture high-quality messenger RNA (mRNA) at lower cost, isolating the mRNA in cellular subcompartments for extraction and GMP-grade production. Its technology targets mRNA-based therapeutics including vaccines for infectious diseases, cancer treatments, and RNA gene therapy for rare diseases.</parameter> <parameter name="founders">[]

1 investor

C2GRID builds a geospatial awareness and decision-support platform that converts video, including drone footage, into near real-time 3D operational environments with multi-sensor data fusion and automated threat detection. It serves military operators and defence and security organisations, with the team also exploring civilian applications such as emergency response, infrastructure monitoring, and industrial inspection.

1 investor

C2MI is a research and development center for electronic systems, offering infrastructure and scientific equipment for microelectromechanical systems (MEMS), advanced semiconductor packaging, compound semiconductors, and printable electronics. It supports both small and large companies in developing microelectronic components from prototyping through commercialization across sectors such as aerospace, agriculture, communications, energy, quantum, and life sciences.

1 investor

Cachai develops collaborative autonomy software that converts hub-dependent systems into consensus-based distributed ones for mission-critical and defense applications. Its technology lets many devices operate as a coordinated swarm that divides tasks and adapts without a single point of failure.

1 investor

Caeli Nova, founded in 2018, develops physiological monitoring technology for fast jet aircrew that aims to improve safety, optimize performance, and reduce operational downtime, drawing on respiratory physiology, medical research, and aerospace engineering. Its roadmap extends to broader military personnel and other sectors where human performance is critical.

1 investor

Calcarea develops a reactor based on "Accelerated Weathering of Limestone" that captures CO2 from point sources—particularly marine on-board applications—and converts it into stable oceanic bicarbonate for permanent storage. The technology, built on oceanography and marine engineering research from Caltech and USC, targets carbon capture and removal in the shipping and climate sectors.

1 investor

CALDRE is a Switzerland-based biotech spin-out developing liver-directed GalNAc-siRNA therapeutics, including its claudin-3 targeting candidate ClagalsiR, to restore bile flow and prevent fibrosis. It aims to treat cholestatic and fibrotic liver diseases such as primary sclerosing cholangitis and primary biliary cholangitis and reduce the need for liver transplantation.

1 investor

Calibrate Ventures is a seed-stage venture capital firm that invests in startups working on AI, automation, autonomy, machine learning, and robotics, partnering with technical founders at the earliest stages.

1 investor

Calycia Bioscience is a biotechnology company developing engineered macrophage cell therapies delivered locally into the brain to target aggressive solid tumors of the central nervous system. Its pipeline focuses on glioblastoma and melanoma brain metastasis within CNS oncology.

1 investor

Cambium develops high-performance advanced materials using AI-driven molecular design and agile domestic manufacturing for extreme-condition applications across aerospace, space, industrial, and defense sectors. The company provides thermal protection systems, structural materials, and specialized protection solutions that are stronger, lighter, and more resilient than conventional alternatives.

1 investor

Cambrian Works builds networking and connectivity infrastructure for satellite communications and space operations, including the GigRouter, a space-ready router and edge-computing device with onboard AI/ML processing. Its products support autonomous data management across hybrid space networks and link systems on Earth and in orbit.

1 investor

Cambrian Vision augments industrial robot arms with computer vision and AI-powered perception capabilities for tasks like bin picking, assembly, and cable handling. The platform includes synthetic data generation, path planning, simulation, and APIs for integration with major robot brands.

1 investor

Cambridge Nucleomics develops a single-molecule RNA counting "nanoarray" assay based on solid-state nanopore and DNA nanotechnology for diagnostic testing. The company applies its technology to RNA biology and microbiology-based diagnostics.

1 investor

CDT is a research and innovation centre focused on the conception, development, and testing of advanced materials, with applications spanning electronics, communications, green energy, and life sciences. It operates as the European Research and Innovation Centre of Sumitomo Chemical.

1 investor

The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample. Its multi-modal liquid biopsy technology is aimed at biomarker discovery and cancer detection for genomics and life sciences research.

1 investor

Canadian Strategic Missions Corporation (CSMC) develops dual-use space and defence technologies through two subsidiaries: CSMC Nuclear, which builds portable micro-nuclear reactors (LEUNR) for remote environments, and CSMC Labs, an R&D division commercializing deep-tech in quantum, robotics, nano-materials, and space systems. Its nuclear reactors target Canadian defence, Indigenous communities, and space exploration.

1 investor

Cantoni Therapeutics is a biotech company developing small molecule bisubstrate inhibitors of the enzyme nicotinamide N-methyltransferase (NNMT) as a treatment for obesity and its cardiometabolic complications such as type 2 diabetes and cardiovascular disease. Its inhibitor portfolio targets both the SAM and NA binding pockets of NNMT, aiming to offer an alternative to appetite-reducing anti-obesity medications.

1 investor

Cape Haven Bio is a venture creation firm focused on translating early-stage academic discoveries into commercially viable biotech companies developing therapeutics. The firm provides strategic planning, lab infrastructure, seed capital, and consulting resources to support the progression from research to investable business.

1 investor

NVentures is NVIDIA's venture capital arm, making strategic investments in technology companies working on AI infrastructure, robotics, digital biology, applied AI, and frontier compute. It builds long-term partnerships with founding teams and provides access to NVIDIA's technical teams, platform integrations, and go-to-market support.

1 investor

Capital 2B is a venture capital firm that invests in deep-tech and IP-led startups from pre-seed to Series A, writing first cheques of $200k–$3M, often as the first institutional investor. It focuses on companies at the intersection of computation, programmable biology, and advanced materials.

1 investor

Capoom provides 3D modeling, 3D scanning, and synthetic data solutions for AI training, simulations, and digital twins across various industries.

1 investor

Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids. The company targets both central nervous system and ophthalmology conditions across all ages.

1 investor